Moody Aldrich Partners’s Intellia Therapeutics NTLA Stock Holding History

Moody Aldrich Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,119	Closed	-$1.13M	–	167
2022 Q3	$1.13M	Buy	+20,119	New	+$1.25M	0.23%	111
2022 Q2	–	Sell	-33,358	Closed	-$2.42M	–	163
2022 Q1	$2.42M	Buy	33,358 +3,700	+12%	+$313K	0.34%	77
2021 Q4	$3.51M	Sell	29,658 -5,342	-15%	-$669K	0.49%	76
2021 Q3	$4.7M	Buy	35,000 +4,809	+16%	+$728K	0.6%	72
2021 Q2	$4.89M	Buy	+30,191	New	+$2.35M	0.69%	68

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Moody Aldrich Partners's NTLA Position: Q4 2022 in Review

Moody Aldrich Partners sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 20,119 shares — an estimated $1.13M sold.

Moody Aldrich Partners first reported a position in NTLA in Q2 2021 and held it in 5 quarters. The position peaked at $4.89M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

Moody Aldrich Partners reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
Moody Aldrich Partners sold 20,119 Intellia Therapeutics shares in Q4 2022, an estimated $1.13M.
Moody Aldrich Partners first reported a position in Intellia Therapeutics in Q2 2021 and held it in 5 quarters.
Moody Aldrich Partners's Intellia Therapeutics position peaked at $4.89M in Q2 2021.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Moody Aldrich Partners's 13F filing for Q4 2022, filed 24 Jan 2023.